Most significant muscle activation values. حسب María Benito-de-Pedro (22057468)

الموضوعات:

Significant repeated measurements sEMG outcomes. حسب María Benito-de-Pedro (22057468)

الموضوعات:

Significant single measurement sEMG outcomes. حسب María Benito-de-Pedro (22057468)

الموضوعات:

Comparative analysis of macronutrient compositions between baseline and end of intervention (*p < 0.05, ^ns Non-significant results). حسب Duc Tran Quang (20564967)

Comparative analysis of caloric intake between baseline and end of intervention (*p < 0.05, ^ns Non-significant results). حسب Duc Tran Quang (20564967)

Comparison of the Non-healed but Improved DUs Based on Initial Wound Area Size in 2022 vs. 2023. حسب Heba Tallah Mohammed (2822432)

Comparison of the Non-healed but Improved PIs Based on Initial Wound Area Size in 2022 vs. 2023. حسب Heba Tallah Mohammed (2822432)

Each subfigure shows a different local size (LS) and context size (CS) configuration, where the reliability of the model across different initializations is measured in R-squared. حسب Eloy Geenjaar (21533195)

الموضوعات:

Distribution of non-pharmacological treatment related to insomnia disorder (2002–2019). حسب Mingee Choi (15250732)

الموضوعات:

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Mean interval from initial diagnosis to initiation of non-pharmacological treatment by year. حسب Mingee Choi (15250732)

الموضوعات:

Anthropometric characteristics of smokers and non-smokers. حسب Prasanna Herath (20714794)

الموضوعات:

Detailed treatment status of people who received non- pharmacological treatment at first diagnosis. حسب Mingee Choi (15250732)

الموضوعات: